HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities To Fund Innovation In An Evolving Global Health And Development Landscape is the 11th annual report by the Working Group, a collaboration among AVAC, UNAIDS, and the International AIDS Vaccine Initiative (IAVI). The report summarizes investment in HIV prevention research across eight prevention options, as well as HSV-2 vaccine and HIV cure and therapeutic vaccine R&D.
19 July 2015 | AVAC
In a first for HIV prevention, researchers have completed follow-up of participants in a pivotal Phase III trial that tested a vaginal ring for preventing HIV in women. The ring, which contains the ARV dapivirine, is meant to be worn for a month at a time. More than 2,600 African women took part in ASPIRE, one of two Phase III trials designed to support potential licensure of the ring. Results are expected early 2016.
29 June 2015 | Eurekalert Medicine & Health
Scientists at the University of York, in conjunction with the York Clinical Research Facility, will start the first phase of trials looking into a new way to prevent HIV transmission.
18 February 2015 | HIV / AIDS News From Medical News Today
The failure of the VOICE trial of H.I.V.-prevention methods in Africa — and the elaborate deceptions employed by the women in it — have opened an ethical debate about how to run such studies in poor countries and have already changed the design of some that are now underway.
05 February 2015 | New York Times
HIV/Aids researchers are anticipating positive results from a large-scale trial assessing the efficacy of a vaginal microbicide gel in preventing HIV infection in women.
21 January 2015 | AllAfrica.com
Dr. Deborah Anderson from Boston University School of Medicine and her colleagues are challenging dogma about the transmission of HIV. Most research has focused on infection by free viral particles, while this group proposes that HIV is also transmitted by infected cells. While inside cells, HIV is protected from antibodies and other antiviral factors. Anderson chides fellow researchers for not using cell-associated HIV in their transmission models: "The failure of several recent vaccine and microbicide clinical trials to prevent HIV transmission may be due in part to this oversight." . The Journal of Infectious Diseases (JID) has devoted their December supplement to this important and understudied topic.
23 December 2014 | Medical News Today
Zeda Rosenberg, Chief Executive Offiver of the International Partnership for Microbicides, says: "While there is much progress to celebrate in HIV treatment and prevention, protecting women remains a major challenge. AIDS is the number-one killer of women ages 15 to 44 worldwide. Women are biologically more vulnerable to infection and face deep-rooted gender inequities that increase their risk. In sub-Saharan Africa, where the epidemic has taken the greatest toll, young women are at least twice as likely to contract HIV as young men."
26 November 2014 | Huffington Post
What do women want? While two trials test vaginal rings to fight HIV, market research highlights respondents’ interests in different options.
14 November 2014 | Science Speaks
Most microbicides work by targeting the virus itself, attempting to break it down or blocking its ability to infect a cell. However, the heightened infectiousness of HIV in the presence of semen appears to over-power any anti-viral effects the microbicides possess. The one exception to this finding is a different type of microbicide that acts on the host cells' receptors, stopping the virus from latching on from within. In the current study, this microbicide, [containing the drug called] called Maraviroc, was equally effective in preventing infection both with and without the presence of semen.
13 November 2014 | MedicalXpress
A recent journal article reviewed the challenges and successes in developing rectal microbicides, including the state of the current field, which we summarize here.
11 November 2014 | BETA blog